TELA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.39 USD | -1.35% |
|
-14.76% | -33.69% |
| Apr. 15 | TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR | CI |
| Mar. 22 | Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating | MT |
Evolution of the average Target Price on TELA Bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
e0a8b2910.CJhNwk-TErXSXA_0qE1gNRS9SCzJT8Yg9OYMqVpdUEk.Oal0gQeiUfGCNFab9wYVDVzEflacJ7xSx49ZkRwQJjs5_gKoJ6dEjOY5Nw~914fd215586aadc951852e46e7457c66
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.39
USD
Average target price
14.6
USD
Spread / Average Target
+232.57%
High Price Target
18
USD
Spread / Highest target
+310.02%
Low Price Target
12
USD
Spread / Lowest Target
+173.35%
Consensus detail
Consensus revision (last 18 months)
Analysts covering TELA Bio, Inc.
| Piper Sandler | |
| JMP Securities |
Trading Rating
Investor Rating
ESG Refinitiv
C-
EPS Revisions
- Stock Market
- Equities
- TELA Stock
- Consensus TELA Bio, Inc.
